Regeneron Pharmaceuticals, Inc.

Top Publications

Top Publications Authored or Co-Authored in "Regeneron Pharmaceuticals, Inc."

• Alirocumab and cardiovascular outcomes after acute coronary syndrome

  New England Journal of Medicine, Volume 379, No. 22, Year 2018, Citations 1997
• Efficacy and safety of alirocumab in reducing lipids and cardiovascular events

  New England Journal of Medicine, Volume 372, No. 16, Year 2015, Citations 1878
• ODYSSEY FH i and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia

  European Heart Journal, Volume 36, No. 43, Year 2015, Citations 478
• Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: The ODYSSEY COMBO II randomized controlled trial

  European Heart Journal, Volume 36, No. 19, Year 2015, Citations 359
• An international effort towards developing standards for best practices in analysis, interpretation and reporting of clinical genome sequencing results in the CLARITY Challenge

  Genome Biology, Volume 15, No. 3, Article R53, Year 2014, Citations 307